Randomized, Stratified, Parallel-group, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 334 in Women With Hot Flashes Associated With Menopause
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Erenumab (Primary)
- Indications Hot flashes; Menopausal syndrome
- Focus Therapeutic Use
- Sponsors Amgen
- 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 02 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 15 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.